{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:26:19Z","timestamp":1793229979949,"version":"4.5.0"},"reference-count":175,"publisher":"The Korean Movement Disorder Society","issue":"4","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["e-jmd.org"],"crossmark-restriction":true},"short-container-title":["JMD"],"published-print":{"date-parts":[[2024,10,31]]},"abstract":"<jats:p>Huntington\u2019s disease (HD) is a neurodegenerative disorder characterized by motor, behavioral, and cognitive impairments and significant impacts on patient quality of life. This evidence-based review, conducted by the Korean Huntington Disease Society task force, systematically examines current pharmacological and nonpharmacological interventions for symptomatic management of HD. Following PRISMA guidelines, databases were searched for studies up to August 2022 that focused on 23 symptoms across four domains: motor, neuropsychological, cognition, and others. This review provides a comprehensive and systematic approach to the management of HD, highlighting the need for more high-quality clinical trials to develop robust evidence-based guidelines.<\/jats:p>","DOI":"10.14802\/jmd.24140","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T23:21:05Z","timestamp":1723159265000},"page":"369-386","update-policy":"https:\/\/doi.org\/10.14802\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evidence-Based Review on Symptomatic Management of Huntington\u2019s Disease"],"prefix":"10.14802","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4182-3612","authenticated-orcid":true,"given":"Jung Hwan","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3593-1134","authenticated-orcid":true,"given":"Hui-Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6415-2316","authenticated-orcid":true,"given":"Jong Hyun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5097-2340","authenticated-orcid":true,"given":"Sungyang","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6086-3199","authenticated-orcid":true,"given":"Seok Jong","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9120-2075","authenticated-orcid":true,"given":"Jee-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4227-7983","authenticated-orcid":true,"given":"Hyun Sook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0277-6326","authenticated-orcid":true,"given":"Manho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Korean Huntington\u2019s Disease Society","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5803","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29228"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2022.0212"},{"key":"ref3","volume-title":""},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241613021"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.14802\/jmd.16022"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12502"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21920"},{"key":"ref8","first-page":"790","volume-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000336533.19610.1b"},{"key":"ref10","first-page":"710","volume-title":"International guidelines for the treatment of Huntington\u2019s disease","author":"Bachoud-L\u00e9vi","year":"2019"},{"key":"ref11","first-page":"25","volume-title":"An MDS evidence-based review on treatments for Huntington\u2019s disease","author":"Ferreira","year":"2022"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0670-4"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200211000-00003"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000198586.85250.13"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/wnf.0b013e3180ca77ea"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21161"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-9-62"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25500"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1685980"},{"key":"ref20","first-page":"40","volume-title":"Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial","year":"2016"},{"key":"ref21","first-page":"494","volume-title":"Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington\u2019s disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial","author":"Furr Stimming","year":"2023"},{"key":"ref22","first-page":"1207","volume-title":"The safety of deutetrabenazine for chorea in Huntington disease: an open-label extension study","author":"Frank","year":"2022"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26014"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1371\/currents.rrn1260"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22188"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.44.5.821"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22376"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.63.1.35"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12706"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200209000-00007"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-322038"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.59.5.694"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000068165.07883.64"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.7.996"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s100720200081"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.63.3.597"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2016.12.003"},{"key":"ref38","first-page":"427","volume-title":"Acute challenge with apomorphine in Huntington\u2019s disease: a double-blind study","author":"Albanese","year":"1995"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21718"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-018-0230-3"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000169025.09670.6d"},{"key":"ref42","first-page":"1582","volume-title":"Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study","year":"2008"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26308"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200201210-00011"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.334"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1001\/2013.jamaneurol.382"},{"key":"ref47","first-page":"152","volume-title":"A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease","author":"McGarry","year":"2017"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.57.3.397"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000070186.97463.a7"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000090629.40891.4b"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-005-0595-4"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000160388.96242.77"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000194318.74946.b6"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000004209"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01919-8"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(14)70262-5"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1017\/neu.2014.16"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26174"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0b013e3181b2ac0a"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173872"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8145-9"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25750"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200001)15:1<173::aid-mds1032>3.0.co;2-t"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000238106.10423.00"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870120319"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.53.5.1000"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.50.5.1366"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14656"},{"key":"ref69","first-page":"465","volume-title":"An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington\u2019s disease","author":"S\u00fcssmuth","year":"2015"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(199911)14:6<1038::aid-mds1024>3.0.co;2-7"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22809"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1097\/npt.0000000000000016"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1177\/0269215512473762"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12053"},{"key":"ref75","first-page":"389","volume-title":"Physical therapy in Huntington\u2019s disease--toward objective assessments?","author":"Bohlen","year":"2013"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20140123"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2016.06.023"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1093\/ptj\/pzx031"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaitpost.2021.03.016"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2022.06.013"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.2340\/16501977-2748"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2004.12.012"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201800619"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1161"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000096019.71649.2b"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000133403.30559.ff"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1177\/0269215513487235"},{"key":"ref88","first-page":"189","volume-title":"Effectiveness of intensive neurorehabilitation in patients with Huntington\u2019s disease","author":"Ciancarelli","year":"2013"},{"key":"ref89","first-page":"A88","volume-title":"K26 specific in-patient rehabilitation improves postural and gait instability in Huntington\u2019s disease","author":"Brabcov\u00e1","year":"2016"},{"key":"ref90","first-page":"301","volume-title":"Inpatient multidisciplinary rehabilitation programme for postural and gait stability in Huntington\u2019s disease \u2013 a pilot study","author":"Brabcov\u00e1","year":"2019"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.pjnns.2015.09.002"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1097\/npt.0000000000000188"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1016\/j.pjnns.2018.02.001"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.3109\/09593985.2015.1110738"},{"key":"ref95","first-page":"S529","volume-title":"Multisensory cues could be effective to improve balance and gait in Huntingtons disease?","author":"Capato","year":"2015"},{"key":"ref96","first-page":"S52","volume-title":"A proposal for a physiotherapy programme to improve gait, balance and functional independence in Huntington\u2019s disease","author":"Capato","year":"2012"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.3389\/fresc.2022.849333"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(11)70233-2"},{"key":"ref99","first-page":"S47","volume-title":"Functional motor outcomes after globus pallidus internus deep brain stimulation in Huntington\u2019s disease - a case report","author":"Capato","year":"2016"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1111\/ner.12098"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.202903"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-014-1201-7"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.68.2.238"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1177\/070674378603100916"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21222"},{"key":"ref106","first-page":"96","volume-title":"[Experience in the use of neuroleptic substances in chronic progressive chorea (Huntington\u2019s chorea)]","author":"Shternberg","year":"1963"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000169732.00690.32"},{"key":"ref108","first-page":"P3.031","volume-title":"A movement disorders paradox: case report of a patient with gene-positive Huntington\u2019s disease who presented with DaTScan positive and levodopa responsive Parkinson\u2019s disease","author":"Hadden","year":"2015"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.65.4.577"},{"key":"ref110","first-page":"A103","volume-title":"Nabilone in Huntington\u2019s disease: a case series of five patients","author":"Heim","year":"2016"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.78.1_meetingabstracts.p06.039"},{"key":"ref112","first-page":"S36","volume-title":"Tetrabenazine: impact on impulsivity scales in Huntington\u2019s disease","author":"Ondo","year":"2020"},{"key":"ref113","first-page":"S22","volume-title":"Long-term efficacy and safety of deutetrabenazine (DTBZ) in patients with chorea associated with Huntington\u2019s disease (HD)","author":"Gordon","year":"2022"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.825532"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-006-7012-5"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1080\/10401230701844802"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.01.002"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.3233\/jhd-170283"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.3233\/jhd-180315"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2022.931636"},{"key":"ref121","first-page":"179","volume-title":"Behavioral and psychiatric symptoms associated with Huntington\u2019s disease","author":"Cummings","year":"1995"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2011.05.006"},{"key":"ref123","first-page":"1188","volume-title":"Risk factors for suicidality in Huntington disease in the context of a randomized clinical trial: an analysis of the 2CARE Study","author":"McGarry","year":"2018"},{"key":"ref124","first-page":"3682","volume-title":"Safety and tolerability of SRX246, a vasopressin 1a antagonist, in irritable Huntington\u2019s disease patients\u2014a randomized phase 2 clinical trial","author":"Brownstein","year":"2020"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1371\/currents.rrn1261"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1080\/13554794.2022.2051562"},{"key":"ref127","first-page":"249","volume-title":"The safety and effectiveness of aripiprazole for treating irritability and aggression in Huntington disease: a double-blind placebo-controlled pilot study","author":"Testa","year":"2016"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08040503"},{"key":"ref129","first-page":"1","volume-title":"Aripiprazole in the treatment of Huntington\u2019s disease: a case series","author":"Ciammola","year":"2009"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.3109\/00048677509159834"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.8.3.338"},{"key":"ref132","first-page":"236","volume-title":"Safety and tolerability of SRX246 in irritable\/aggressive subjects with Huntington\u2019s disease (stair): a phase II exploratory clinical trial","author":"Raulerson","year":"2018"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.6.2.154"},{"key":"ref134","first-page":"69","volume-title":"Short-term effects of olanzapine in Huntington disease","author":"Squitieri","year":"2001"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1016\/s0738-3991(02)00070-8"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1097\/wnf.0b013e3181ebb285"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116522"},{"key":"ref138","first-page":"e131","volume-title":"Hypersexual features in Huntington\u2019s disease","author":"Jhanjee","year":"2011"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410370516"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.1093\/arclin\/acx086"},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.3233\/jhd-170241"},{"key":"ref142","first-page":"165","volume-title":"Safety and efficacy of pridopidine in patients with Huntington\u2019s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study","author":"Reilmann","year":"2019"},{"key":"ref143","first-page":"239","volume-title":"Cognitive function in early clinical phase huntington disease after rivastigmine treatment","author":"Se\u0161ok","year":"2014"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000240945.44370.f0"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.312"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.1371\/currents.hd.9504af71e0d1f87830c25c394be47027"},{"key":"ref147","first-page":"A103","volume-title":"A prospective trial for pallidal deep brain stimulation in Huntington\u2019s disease","author":"Vesper","year":"2016"},{"key":"ref148","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.02.030"},{"key":"ref149","doi-asserted-by":"publisher","DOI":"10.3171\/2014.2.jns131722"},{"key":"ref150","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2017.04.002"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.395"},{"key":"ref152","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2017-0019"},{"key":"ref153","doi-asserted-by":"publisher","DOI":"10.1016\/s2215-0366(16)30355-8"},{"key":"ref154","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.47.1.70"},{"key":"ref155","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200001)15:1<171::aid-mds1031>3.0.co;2-y"},{"key":"ref156","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1129"},{"key":"ref157","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.16.3.381-a"},{"key":"ref158","doi-asserted-by":"publisher","DOI":"10.3390\/toxins5051010"},{"key":"ref159","doi-asserted-by":"publisher","DOI":"10.1177\/0269215514564087"},{"key":"ref160","doi-asserted-by":"publisher","DOI":"10.1177\/0269215514540921"},{"key":"ref161","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1190563"},{"key":"ref162","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2021.06.015"},{"key":"ref163","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01319.x"},{"key":"ref164","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000031791.10922.cf"},{"key":"ref165","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000334276.09729.0e"},{"key":"ref166","doi-asserted-by":"publisher","DOI":"10.2217\/nmt.11.69"},{"key":"ref167","doi-asserted-by":"publisher","DOI":"10.3233\/jhd-170264"},{"key":"ref168","first-page":"135","volume-title":"Mitochondrial dysfunction, metabolic deficits, and increased oxidative stress in Huntington\u2019s disease","author":"Chen","year":"2011"},{"key":"ref169","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.017822"},{"key":"ref170","first-page":"217","volume-title":"Severe jaw dystonia causing weight loss in a young adult with Huntington\u2019s disease relieved by tizanidine","author":"Mortimer","year":"2014"},{"key":"ref171","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04265-0"},{"key":"ref172","doi-asserted-by":"publisher","DOI":"10.1097\/01376517-198904000-00005"},{"key":"ref173","doi-asserted-by":"publisher","DOI":"10.1007\/bf02493441"},{"key":"ref174","first-page":"1","volume-title":"A home program of speech therapy in Huntington\u2019s disease","author":"Giddens","year":"2010"},{"key":"ref175","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.106049"}],"updated-by":[{"DOI":"10.14802\/jmd.24140e","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000}}],"container-title":["Journal of Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-jmd.org\/upload\/pdf\/jmd-24140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-jmd.org\/journal\/view.php?doi=10.14802\/jmd.24140","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-jmd.org\/upload\/pdf\/jmd-24140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T23:24:53Z","timestamp":1732836293000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-jmd.org\/journal\/view.php?doi=10.14802\/jmd.24140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":175,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"URL":"https:\/\/doi.org\/10.14802\/jmd.24140","relation":{"correction":[{"id-type":"doi","id":"10.14802\/jmd.24140e","asserted-by":"object"}]},"ISSN":["2005-940X","2093-4939"],"issn-type":[{"value":"2005-940X","type":"print"},{"value":"2093-4939","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]},"assertion":[{"value":"2024-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-09","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-31","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}